SCHEMBL31708065

SCHEMBL31708065

C#C[C@@](C)(O)c1cc(OC)nc(OC)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ PDE2A O00408 3/20 0.37
▸ ALDH1A1 P00352 3/20 0.36
▸ CYP3A4 P08684 2/20 0.36
▸ HTR6 P50406 1/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ AKT1 P31749 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ ALOX12 P18054 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ NPC1 O15118 2/20 0.34
▸ RAB9A P51151 2/20 0.34
▸ TP53 P04637 1/20 0.34
▸ NFKB1 P19838 1/20 0.34
▸ NFKB2 Q00653 1/20 0.34
▸ RELA Q04206 1/20 0.34
▸ CYP1A2 P05177 2/20 0.33
▸ EDNRB P24530 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31708108 0.84 PDE2A (0.51) PDE2AALDH1A1CYP1A2KDM4E
SCHEMBL31708020 0.84 HRH4 (0.33) PDE2AHRH4HSD17B10
SCHEMBL10220211 0.77 HRH4 (0.50) LMNATDP1ALDH1A1CYP3A4HTR6
SCHEMBL25217067 0.75 CYP2C19 (0.35) PDE2AALDH1A1SMN1; SMN2KMT2AHTT
SCHEMBL31708045 0.75 CYP2C19 (0.35) PDE2AALDH1A1SMN1; SMN2KMT2AHTT
SCHEMBL31708110 0.74 FFAR1 (0.33) —
SCHEMBL15218853 0.73 LMNA (0.45) LMNATDP1ALDH1A1CYP3A4HTR6
SCHEMBL25239087 0.72 PDE2A (0.33) TDP1PDE2ASMN1; SMN2
SCHEMBL439716 0.70 LMNA (0.59) LMNATDP1PDE2AALDH1A1CYP3A4
SCHEMBL31708038 0.66 HSP90AA1 (0.32) PDE2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4143179-B1 AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER IDORSIA PHARMACEUTICALS LTD (CH) 2025-10-22 — — EP disclosed
Send feedback